Emerging from a collaborative effort spearheaded by researchers at The Wistar Institute and Temple University, a novel metabolic pathway has been illuminated, offering a groundbreaking avenue to tackle ovarian cancers that are adept at DNA repair. The collaborative study, published in the prestigious journal Nature, reveals that alpha-ketoglutarate (αKG), a key metabolic intermediate, accumulates in DNA repair proficient ovarian tumors and plays an unexpected but crucial role in facilitating DNA repair. This discovery overturns conventional assumptions focused solely on αKG’s role in demethylation and opens an unprecedented window into metabolic regulation linked to genome maintenance.

The crux of this research hinges on αKG’s capacity to activate an enzyme called TMLHE, previously unassociated with DNA repair mechanisms. TMLHE catalyzes the initial step in the biosynthesis of carnitine, a metabolite widely recognized for its role in energy metabolism by transporting fatty acids into mitochondria. This metabolic axis—αKG to TMLHE to carnitine production—has now been implicated as a pivotal driver of histone acetylation, a modification that relaxes the tight packaging of DNA around histone proteins. This loosening of chromatin structure is essential for the DNA repair machinery to access and mend damaged genomic regions effectively.

Through the innovative application of CRISPR-based screening technology, the research team systematically identified TMLHE as the linchpin enzyme enabling αKG’s influence on DNA repair. This enzyme had been overlooked by the scientific community, which traditionally linked αKG’s functions exclusively to its role as a cofactor for demethylases. The revelation that TMLHE-mediated carnitine synthesis facilitates histone acetylation fundamentally shifts our understanding of metabolic regulation in cancer cells, underscoring a unique acetylation pathway independent of the known methylation pathways governed by αKG.

Carnitine’s newly discovered role transcends its classical function of mitochondrial fatty acid transport. It acts as a molecular courier, shuttling acetyl groups—key metabolic intermediates—out of mitochondria and into the cell nucleus. Within the nucleus, these acetyl groups are deposited onto histones via acetylation, thereby modulating chromatin accessibility. This biochemical maneuver is integral to efficient DNA repair, as it dictates the spatial dynamics of DNA repair complexes. By modulating histone acetylation, carnitine effectively orchestrates the structural environment necessary for repair proteins to rectify DNA lesions inflicted by chemotherapy.

Crucially, inhibition experiments targeting TMLHE or the carnitine biosynthesis pathway demonstrated a pronounced impairment in histone acetylation at critical chromatin sites. This biochemical blockade hinders the assembly of DNA repair machinery, sensitizing cancer cells to DNA-damaging chemotherapeutic agents such as platinum-based drugs. These findings hold significant therapeutic promise, suggesting that dual targeting of metabolic pathways and DNA repair mechanisms can synergistically overcome chemoresistance and improve clinical outcomes in ovarian cancer patients.

The translational potential of these insights was underscored by preclinical studies employing mildronate, a clinically tolerated inhibitor of carnitine synthesis. When administered concomitantly with cisplatin in mouse models, mildronate significantly curtailed tumor growth, whereas either agent alone elicited minimal effects. This combinatorial approach exemplifies a practical strategy to subvert DNA repair proficiency in tumors, advocating for clinical trials assessing carnitine synthesis inhibitors as adjuvants in chemotherapy regimens.

Further supporting the clinical relevance, patient-derived data revealed that elevated TMLHE expression in tumor biopsies correlated strongly with diminished progression-free survival following chemotherapy. Concurrently, higher serum levels of acetylcarnitine at diagnosis independently predicted accelerated disease progression, presenting an opportunity for biomarker-driven patient stratification. These findings hint at the feasibility of utilizing blood-based tests to identify ovarian cancer patients with treatment-resistant phenotypes and to tailor combination therapies accordingly.

The ramifications of this discovery extend far beyond ovarian cancer alone. Given that αKG is a central metabolic regulator and its levels decline with aging, the elucidated pathway offers a profound new lens through which to investigate gene regulation, genomic integrity, and cellular aging processes. Histone acetylation, modulated via αKG-driven carnitine metabolism, emerges as a vital nexus connecting metabolism to the maintenance of DNA stability, with far-reaching implications across cancer biology, stem cell research, and developmental biology.

This paradigm-shifting study was achieved through an exemplary interdisciplinary collaboration, weaving together expertise in metabolomics, biochemistry, molecular biology, and clinical oncology. The integration of advanced mass spectrometry, molecular genetics, and animal modeling facilitated the comprehensive mapping of the αKG-TMLHE-carnitine axis within cellular and patient tumor contexts. This collective effort epitomizes the power of scientific community and cross-institutional partnerships in addressing complex biomedical challenges.

Dr. Katherine Aird, the senior author and co-leader of the Molecular and Cellular Oncogenesis Program at Wistar, reflected on the unexpected nature of the findings: “Everyone in the field expected the focus to be on demethylases, but discovering TMLHE as a key player revealed an unanticipated metabolic mechanism driving DNA repair.” Nathaniel Snyder, co-senior author and expert in cardiovascular discovery at Temple University, emphasized the novelty of this distinct acetylation pathway controlled by αKG, highlighting its essential role in DNA repair—a biological insight hitherto unrecognized.

Collectively, these findings paint a vibrant portrait of metabolic control of epigenetic regulation, unveiling therapeutic vulnerabilities in chemoresistant ovarian cancers. By harnessing the power of metabolic intervention, there is now a tangible pathway to thwart the resilience of these aggressive tumors, offering renewed hope for patients facing limited treatment options. This advancement not only charts a new course in cancer therapy but also enriches our fundamental understanding of the intertwined nature of metabolism, epigenetics, and genome stability in human health and disease.

Subject of Research: Animals

Article Title: αKG-mediated carnitine synthesis drives DNA repair via histone acetylation

News Publication Date: 27-May-2026

Web References:

• Research Article: https://www.nature.com/articles/s41586-026-10584-7
• DOI: http://dx.doi.org/10.1038/s41586-026-10584-7

References:
Apoorva Uboveja et al., “αKG-mediated carnitine synthesis drives DNA repair via histone acetylation,” Nature, 2026.

Image Credits: The Wistar Institute

Keywords: Ovarian cancer, DNA damage responses, alpha-ketoglutarate, carnitine synthesis, histone acetylation, DNA repair, chemotherapy resistance, TMLHE enzyme, metabolic pathways, epigenetics, cancer metabolism, platinum-based chemotherapy

Genomic stability is the cornerstone of cellular health, with DNA repair mechanisms playing an essential role in preventing mutations that could trigger malignant transformation. A critical insight of this research highlights that the homologous recombination pathway responsible for repairing DNA breaks is not static but exhibits robust circadian oscillations. The efficiency of DNA repair mechanisms fluctuates throughout the day, with peak activity occurring in the early morning hours and subsequently fading toward nighttime before rising again during the nocturnal phase of the cycle.

Central to this temporal regulation is CRY1, a core protein component of the molecular circadian clock. CRY1 functions as a modulator that suppresses DNA end resection, a key initial step in homologous recombination. The researchers discovered that when CRY1 levels diminish during the morning, DNA repair is at its most proficient, allowing cells to effectively rectify DNA double-strand breaks. In contrast, elevated CRY1 levels in the afternoon and evening hours act as a brake, dampening the repair machinery and increasing cellular vulnerability to DNA-damaging agents such as ionizing radiation.

This intimate link between circadian biology and DNA repair has profound implications for cancer progression and treatment. Tumors characterized by high CRY1 expression were shown to be more radiosensitive, which suggests that the timing of radiation delivery could be strategically optimized to exploit periods of reduced DNA repair capacity. By administering radiotherapy when CRY1 concentrations are elevated—typically later in the day—oncologists could enhance cancer cell killing while potentially sparing normal tissue with more efficient repair capacity.

Clinically, a retrospective analysis of patient data from the Virgen Macarena University Hospital substantiated these laboratory findings. Breast cancer patients receiving radiotherapy during afternoon and evening hours exhibited markedly improved overall survival compared to those treated earlier in the day. This temporal specificity in treatment outcomes was further observed in prostate cancer patients but did not extend to lung cancers or gliomas, underscoring the nuanced interplay between circadian regulation and cancer type.

The phenomenon known as chronoradiotherapy, which tailors radiation treatment to the body’s biological clock, emerges as a promising therapeutic avenue from this research. By aligning radiotherapy schedules with the rhythmic expression of CRY1 and other circadian factors, clinicians may be able to maximize DNA damage in tumor cells when their repair systems are least active, thereby improving the efficacy of treatment protocols and patient prognoses.

Mechanistically, the study provides a detailed molecular framework showing how CRY1 directly interferes with DNA end resection enzymes, hindering their ability to process DNA breaks efficiently. This disruption results in a controlled attenuation of homologous recombination, a high-fidelity repair pathway crucial for maintaining chromosomal integrity. The fine-tuning of this pathway by the circadian clock represents an elegant evolutionary adaptation that balances genome maintenance with cellular metabolic states that fluctuate throughout the day.

The implications of this discovery extend beyond cancer therapy. Understanding circadian influences on DNA repair pathways could illuminate broader aspects of human health and disease, including aging and neurodegeneration, where DNA damage accumulation plays a critical role. Such insights pave the way for exploring pharmacological modulation of clock proteins like CRY1 to enhance DNA repair capacity under conditions of stress or disease.

This research also underscores the importance of considering temporal biological factors in clinical protocols, advocating for a paradigm shift where the timing of drug administration, radiation exposure, or surgical interventions are optimized based on circadian biology. Integrating chronobiology into personalized medicine has the potential to transform treatment outcomes across a spectrum of disorders linked to genomic instability.

The findings prompt further investigation into the molecular crosstalk between circadian regulators and DNA damage response elements. Elucidating these pathways could yield novel biomarkers for cancer prognosis and new targets for therapeutic intervention. Additionally, the differential impact observed among distinct cancer types calls for more comprehensive studies examining how tumor-specific molecular landscapes interact with circadian dynamics.

In conclusion, this seminal study establishes a crucial link between the circadian protein CRY1 and the temporal regulation of homologous recombination-mediated DNA repair. By demonstrating how CRY1-mediated dampening of DNA break repair modulates cellular sensitivity to radiotherapy, the research opens exciting opportunities for chronotherapy approaches that exploit the natural rhythms of cellular repair. This advancement represents a significant leap toward precision cancer treatment informed by the intrinsic biological clocks governing human physiology.

Subject of Research: Circadian regulation of DNA repair mechanisms in human cells and its impact on radiotherapy effectiveness

Article Title: Circadian regulation of homologous recombination by cryptochrome1-mediated dampening of DNA end resection

News Publication Date: 1-Dec-2025

Web References: http://dx.doi.org/10.1038/s41467-025-65854-1

Keywords: Radiation therapy, Cancer treatments, Medical treatments, Clinical medicine, Health and medicine, Human health

Germline DNA repair mechanisms are fundamental processes that correct mutations and maintain the genetic integrity of cells. When these mechanisms fail, patients become susceptible to various forms of cancer, including gastrointestinal malignancies. The study set out to investigate whether inherited defects in DNA repair could significantly contribute to the early onset of such cancers. The results were both surprising and illuminating, suggesting that specific genetic disruptions can lead to a predisposition for developing cancers at a notably younger age than is typically observed.

The research emphasized the role of double-strand break repair pathways in the germline, such as homologous recombination and non-homologous end joining. These pathways are responsible for repairing DNA that has been damaged or incorrectly replicated. When these pathways are dysfunctional due to genetic mutations, it may set the stage for uncontrolled cell growth, leading directly to the formation of tumors. This correlation underscores the need for improved genetic screening protocols in individuals with a family history of gastrointestinal cancers.

In essence, the researchers conducted a comprehensive analysis of patients diagnosed with early-onset gastrointestinal cancer, comparing their genetic profiles against control groups. Through whole-exome sequencing, they were able to identify a pattern of mutations that correlated strongly with deficiencies in DNA repair mechanisms. This sequencing enabled the researchers to pinpoint specific genes that, when mutated, contributed to an overall increase in cancer risk. The team’s findings indicate that these mutations may disrupt critical cellular processes, prompting oncogenesis.

Additionally, the study examined the biochemical pathways influenced by the identified genetic mutations. The researchers noted that certain defects led to aberrant signaling cascades that promote cell survival in the context of DNA damage. This altered response to stress signals could explain why some individuals with these genetic predispositions develop cancer much earlier in life than others without these mutations.

As we begin to comprehend the mechanistic underpinnings of DNA repair deficiencies, it becomes clear that early intervention is critical. The researchers propose that genetic screening for individuals with a known family history of gastrointestinal cancers could be pivotal in identifying at-risk populations. This proactive approach can permit the implementation of precision prevention strategies, tailored specifically to address an individual’s unique genetic makeup.

Moreover, the implications of this research extend far beyond merely identifying genetic risk factors. The potential for developing targeted therapies that address specific DNA repair deficiencies could revolutionize treatment approaches for patients diagnosed with early-onset gastrointestinal cancers. By harnessing the knowledge gained from this research, clinicians may be able to devise more effective treatment plans that not only target the tumor but also correct the underlying genetic issues contributing to tumorigenesis.

The study’s findings contribute to a growing body of literature indicating that cancer is not exclusively an environmental disease but is often significantly influenced by genetic components. This paradigm shift may encourage further research into the role that other inherited genetic factors play in cancer predisposition, particularly in gastrointestinal oncology. Furthermore, insights gained from this research could spur additional studies focusing on other cancers associated with DNA repair deficiencies.

The researchers acknowledge that while their findings represent a significant advancement, further validation is crucial. They call for larger cohorts to corroborate the association they observed, highlighting the need for collaborative efforts across different institutions to assemble a more comprehensive dataset. This collaborative framework could help establish robust genetic predisposition models that inform both clinical practice and public health initiatives.

In parallel to the scientific rigors of validation, there is also a pressing need for increased awareness surrounding genetic testing for cancer predisposition. As the medical community increasingly recognizes the importance of genetics in cancer risk, patients and families must be informed of available testing options and their implications. Education about genetic counseling and the potential benefits of proactive screening could facilitate earlier diagnosis and intervention, ultimately improving patient outcomes.

As the landscape of oncology continues to evolve, researchers call for an integrated approach that encompasses genetic insights, preventive strategies, and innovative therapies. This coalition of efforts has the potential to not only enhance our understanding of gastrointestinal cancers but also to inform comprehensive prevention strategies that are precise and individualized. The notion that treatment can be tailored based on an individual’s genetic profile highlights a burgeoning era of personalized medicine, wherein healthcare can be more responsive to patient needs and risks.

In conclusion, the pioneering research conducted by Yang, Zhang, and Ge lays a crucial foundation for future investigations into the intricate relationship between genetic factors and cancer emergence. The identification of germline DNA repair deficiencies as significant contributors to early-onset gastrointestinal cancers is a call to action for the scientific and medical communities alike. By advancing our understanding of these complex interactions, we can take meaningful strides towards effective prevention and treatment paradigms that will not only enhance patient care but also potentially save lives.

As the implications of this study are further explored and expanded upon, the expectation is that it will garner attention not only within academic spheres but also resonate with a broader audience. The narrative of genetics and cancer, once confined to the realms of scientific journals, is now at the forefront of public health discussions—prompting conversations that are both timely and necessary as we advance towards more nuanced and effective healthcare solutions.

Subject of Research: Deficiencies in germline DNA repair associated with early-onset gastrointestinal cancers.

Article Title: Deficiencies in germline DNA repair are associated with early-onset gastrointestinal cancers and inform precision prevention strategies.

Article References:

Yang, W., Zhang, Y., Ge, M. et al. Deficiencies in germline DNA repair are associated with early-onset gastrointestinal cancers and inform precision prevention strategies.
J Transl Med (2025). https://doi.org/10.1186/s12967-025-07595-9

Image Credits: AI Generated

DOI: 10.1186/s12967-025-07595-9

Keywords: DNA repair deficiency, gastrointestinal cancers, genetic predisposition, cancer prevention, personalized medicine.

The X-ray repair cross-complementing group 3 (XRCC3) gene is integral in the DNA repair process, specifically in the homologous recombination repair pathway. As DNA damage accumulates, particularly due to environmental factors or endogenous stresses, the efficacy of DNA repair mechanisms becomes crucial in determining an individual’s risk of cancer. Variations in DNA repair genes, like XRCC3, can lead to significant disparities in repair efficiency, thereby influencing susceptibility to various cancers, including thyroid malignancies.

In the context of the study, researchers meticulously gathered and analyzed existing literature to establish a correlation between specific polymorphisms within the XRCC3 gene and thyroid cancer. The comprehensive nature of this work sheds light on the complexities of genetic architecture that may predispose certain individuals to this form of cancer. Notably, variations such as the Thr241Met polymorphism have been highlighted for their potential role in modulating cancer risk. By integrating genomic data with epidemiological findings, the study provides a robust framework for understanding the pathogenic mechanisms involved in thyroid cancer.

The implications of these findings extend beyond mere genetic predisposition; they emphasize the necessity of genetic screening in populations at risk. If certain XRCC3 polymorphisms are confirmed to significantly heighten the risk for thyroid cancer, then targeted screening strategies could be designed to identify individuals most likely to benefit from preventive measures or early interventions. Moreover, such stratification could refine treatment approaches, aligning them closely with individual genetic profiles to enhance efficacy and minimize adverse effects.

As part of their methodology, the researchers employed meta-analytic techniques that allowed them to synthesize data from various studies, enhancing the reliability of their conclusions. The rigorous statistical analyses undertaken highlight the importance of multidisciplinary approaches in cancer research, where geneticists, epidemiologists, and oncologists converge to decipher the multifactorial nature of cancer etiology. By collating and interpreting vast data sets, the researchers significantly contribute to our understanding of the XRCC3 gene’s role in cancer susceptibility.

This research resonates with ongoing discussions in the scientific community regarding the cancer genome and the importance of personalized medicine. With the rapid advancements in genomic sequencing technologies, the opportunity to tailor cancer therapy based on genetic risk profiles is becoming increasingly feasible. A deeper understanding of XRCC3 polymorphisms could lead to innovative therapeutic strategies that not only target cancer cells more effectively but also mitigate the risk of developing cancer in genetically predisposed individuals.

Furthermore, the findings underscore the need for further studies to validate and expand upon the identified associations. The relationship between genetics and cancer is complex, influenced by countless factors including environmental exposures and lifestyle choices. Future research efforts should aim to explore these interactions comprehensively, providing a holistic view of thyroid cancer susceptibility that integrates both genetic and non-genetic factors.

In addition to advancing scientific knowledge, this study carries potential implications for public health policy. By identifying genetic markers associated with heightened cancer risk, health authorities could implement targeted education and outreach programs, particularly in regions with higher incidences of thyroid cancer. Public health initiatives that promote awareness about genetic predispositions could empower individuals with the knowledge necessary to make informed decisions regarding their health and seek preemptive care.

The landscape of cancer research is ever-evolving, and studies such as the one conducted by Khosravi-Mashzi et al. are indispensable in shaping our understanding of this complex disease. As investigations into genetic polymorphisms continue to unfold, the integration of these findings into clinical practice will be paramount. This intersection of research and clinical application holds the promise of transforming cancer prevention and treatment paradigms, ultimately contributing to improved patient outcomes and survival rates.

In conclusion, the extensive exploration of XRCC3 polymorphisms presented in this study catalyzes a new wave of inquiry into the genetic determinants of thyroid cancer. While significant progress has been made, it is essential for the scientific community to remain vigilant and continue investigating these associations. The hope is that such efforts will lead to the development of more effective prevention strategies and novel therapeutic modalities, ensuring that we are not only combating cancer but also advancing toward an era of personalized healthcare where we can tailor interventions to the unique genetic profile of each individual.

This research is a call to action, underscoring the urgency for continued investment in genetic research, comprehensive screening programs, and patient education. Together, these elements can significantly alter the trajectory of thyroid cancer outcomes and empower individuals facing this formidable challenge. As we advance toward a future where our understanding of genetics and cancer intricately intertwine, it is clear that such collaborative efforts are vital for the continued fight against cancer in all its forms.

Subject of Research: The association between XRCC3 polymorphisms and thyroid cancer susceptibility.

Article Title: A comprehensive compilation of data on the association between XRCC3 polymorphisms and thyroid cancer susceptibility.

Article References: Khosravi-Mashzi, M., HaghighiKian, S.M., Naseri, A. et al. A comprehensive compilation of data on the association between XRCC3 polymorphisms and thyroid cancer susceptibility. BMC Endocr Disord 25, 231 (2025). https://doi.org/10.1186/s12902-025-02044-6

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12902-025-02044-6

Keywords: XRCC3, thyroid cancer, genetic polymorphisms, cancer susceptibility, DNA repair, personalized medicine, public health.

The findings emerged from a comprehensive analysis involving multiple tumor types, exploring the role of C1orf50 across various cancers. Ovarian cancer, in particular, has long been acknowledged for its complex molecular landscape, and C1orf50’s involvement in key cellular functions like DNA repair is indeed noteworthy. This gene appears to play a significant role in maintaining genomic stability — a crucial factor for preventing mutations that can lead to tumorigenesis.

C1orf50 has garnered attention in cancer research due to its potential mechanisms impacting DNA repair pathways. Specifically, the study investigates how this gene interacts with existing cellular repair systems when DNA damage occurs. Proficient DNA repair is vital for the survival of tumor cells, allowing them to resist conventional therapies that aim to induce DNA damage. Understanding how C1orf50 coordinates with these pathways could facilitate the development of targeted therapies that enhance the efficacy of existing treatments.

The ramifications of C1orf50’s involvement extend beyond genetic repair. The study highlights its role in immune modulation, an area that is gaining traction in oncology as immune evasion is a hallmark of many cancers, including ovarian. By investigating how C1orf50 affects the immune microenvironment around tumors, the research delves into whether enhancing the immune response could be a viable strategy for combating ovarian cancer, potentially leading to better patient outcomes.

In light of these findings, the potential for therapeutic interventions targeting C1orf50 emerges. The study meticulously details how inhibiting or upregulating this gene might impact overall tumor behavior and immune interactions. Given the current landscape of immunotherapy, this presents an exciting new direction that aligns with the ongoing quest in the field to rejuvenate immune responses against tumors.

Moreover, the integration of C1orf50 profiling across various cancer types elucidates its pan-cancer significance. This broad perspective not only amplifies its relevance in ovarian cancer but also positions it as a candidate for further exploratory studies across different malignancies. The pan-cancer profiling methodology applied in this research provides a framework for understanding shared genetic vulnerabilities across diverse tumor presentations, a concept that could lead to novel therapeutic strategies that transcend specific cancer types.

Furthermore, the implications for personalized medicine also arise from this study. As clinicians strive to tailor therapies to individual patient profiles, incorporating biomarkers like C1orf50 may inform treatment decisions, offering a pathway towards more effective and individualized cancer care. This aligns with the growing understanding that a one-size-fits-all approach to cancer treatment is increasingly outdated.

Researchers have also discussed the necessity for additional studies to confirm and expand upon these findings. Investigating the mechanisms by which C1orf50 regulates both DNA repair and immune evasion could elucidate crucial pathways that have been overlooked in current oncology research. There’s a pressing need to explore how the modulation of this gene influences tumor progression and patient responses to therapies, particularly in clinical settings.

Given the current advancements in genomic and proteomic technologies, future research endeavors are likely to validate and operationalize these findings. The goal will be to not only elucidate C1orf50’s function but also translate these insights into viable clinical applications that could one day improve survival rates and quality of life for ovarian cancer patients.

In summary, Rogachevskaya et al.’s study represents a significant leap forward in our understanding of the interplay between genetics, cancer biology, and immune response. By connecting C1orf50 to pivotal roles in DNA repair and immune modulation in ovarian cancer, the research sets the stage for invigorated efforts in therapeutic development. Patients and healthcare providers alike may soon benefit from innovative strategies rooted in this groundbreaking genetic research, underscoring the importance of continued investment in comprehensive cancer studies.

As the scientific community digests these findings, the anticipation for clinical trials targeting C1orf50-specific pathways continues to grow. Progressing from laboratory insights to therapeutic outcomes is a challenging yet rewarding journey fraught with both obstacles and opportunities. With collaboration across disciplines, the potential for meaningful advancements in ovarian cancer treatment emerges on the horizon.

In conclusion, the extensive research linking C1orf50 to significant biological processes in ovarian cancer not only lays the groundwork for future investigations but also highlights the importance of individual genes in the broader narrative of cancer treatment and biology. The journey towards unraveling the complexities of ovarian cancer is ongoing, but studies such as this markedly contribute to the wisdom necessary for conquering this formidable disease.

Subject of Research: C1orf50 in ovarian cancer and its roles in DNA repair and immune modulation.

Article Title: Pan-cancer profiling links C1orf50 to DNA repair and immune modulation in ovarian cancer.

Article References:

Rogachevskaya, A., Otani, Y., Ohtsu, A. et al. Pan-cancer profiling links C1orf50 to DNA repair and immune modulation in ovarian cancer. J Ovarian Res (2025). https://doi.org/10.1186/s13048-025-01916-8

Image Credits: AI Generated

DOI:

Keywords: C1orf50, ovarian cancer, DNA repair, immune modulation, pan-cancer profiling, personalized medicine.

At the core of this study is the intricate relationship between DNA repair pathways and cancer cell survival. The research emphasizes the pivotal role that DNA double-strand break repair mechanisms play in cellular responses to DNA damage. Ovarian cancer, characterized by its high rates of genetic mutations and compromised DNA repair pathways, has historically proven to be resistant to standard therapies. Given the importance of DNA repair in maintaining genomic stability, understanding the role of various repair mechanisms can illuminate new treatment strategies.

The study meticulously explores the role of Mcl1, a protein critical to cellular survival, in mediating this shift from homologous recombination (HR) to non-homologous end joining (NHEJ)—two primary pathways through which cells repair DNA. In normal physiological conditions, HR is generally favored due to its precision and accuracy in repairing double-strand breaks. However, as the research indicates, GX15-070 facilitates a complex interaction with Mcl1, nudging the repair process towards the less accurate NHEJ pathway. This foundational shift underlines the potential for increased vulnerability in cancer cells, especially when combined with the PARP inhibition provided by niraparib.

Moreover, the implications of this research extend beyond ovarian cancer. The ability to manipulate the DNA repair pathway could revolutionize therapeutic approaches across various malignancies that exhibit similar characteristics. By understanding how to modulate the activity of critical proteins like Mcl1, researchers can explore innovative combination therapies that might enhance the efficacy of existing treatments while minimizing the risk of resistance—an ever-present hurdle in cancer therapy.

As researchers delve deeper into the molecular mechanisms at play, the study offers a treasure trove of data highlighting the precise interactions that underpin these shifts. Detailed analysis revealed that the combined treatment of GX15-070 and niraparib not only improves cell death rates in ovarian cancer models, but also alters gene expression profiles indicative of a shift in repair strategies. Such results provide an invaluable foundation for subsequent clinical trials and could potentially signal a new era in cancer treatment where tailored therapies based on individual tumor profiles could lead to much-needed breakthroughs.

In addition to elucidating these molecular dynamics, the study intricately examines the implications of drug interactions on cellular tolerance and therapeutic resistance. As GX15-070 shifts the balance toward NHEJ, there exists a tangible risk that cancer cells might adapt over time, necessitating rigorous monitoring and the development of additional combination strategies to prevent resistance. These considerations bear great weight on the future landscape of cancer pharmacotherapy, showcasing that innovation must go hand-in-hand with vigilance.

The importance of using clinical models allows researchers to observe these interactions in a more authentic environment, drawing parallels to patient responses. This study thus stands as a beacon of hope, pointing towards a potential pathway whereby more effective treatment regimens can emerge. As researchers strive to bridge bench research with clinical applications, the findings of Sheng et al. underscore the imperative for ongoing collaboration between molecular biologists, oncologists, and pharmacologists to elevate cancer treatment to new heights.

In view of the findings, it is compelling to consider the strategic implications for drug development moving forward. The molecular insights gathered from this study could guide pharmaceutical companies and research institutions in fine-tuning existing drugs or designing novel compounds aimed at enhancing the antitumor effects while concurrently minimizing adverse effects. The dual approach of leveraging both PARP inhibition alongside strategic modulation of DNA repair pathways can herald more lasting therapeutic responses in the complex landscape of cancer.

Building upon these results, further investigations will focus on the safety and efficacy of this combined treatment in diverse populations. Questions remain regarding optimal dosing strategies, the timing of drug administration, and the identification of specific biomarkers that may predict response to such innovative treatment combinations. These avenues of research will be essential to ensure that this emerging therapeutic strategy can be adopted effectively in clinical practices.

The enthusiasm generated by this study reflects a broader trend in oncology toward individualized medicine. The potential to tailor treatments based on a patient’s unique tumor biology presents a transformative shift away from the one-size-fits-all paradigm that has long defined cancer care. Researchers are eager to explore how findings from studies like Sheng et al. can be integrated within ongoing clinical trials that prioritize patient outcomes and quality of life.

In conclusion, the breakthrough findings articulated in this research article motivate an optimistic outlook for future therapies in ovarian cancer and beyond. By elucidating the interplay between GX15-070, niraparib, and Mcl1-mediated pathways, this study forms a cornerstone for future research aimed at combatting the formidable challenges posed by various cancers. As we stand on the precipice of a transformative era in oncology, the integration of molecular insights with clinical strategies has never been more essential.

The future of cancer treatment may very well hinge on similar studies that not only enhance our understanding of tumor biology but also spur innovation in drug development. Embracing the complexity of cancer through comprehensive research will be pivotal in overcoming the limitations of existing therapies and ultimately improving patient outcomes across the globe.

Subject of Research: Ovarian cancer treatment enhancement through modulation of DNA repair pathways.

Article Title: GX15-070 enhances niraparib efficacy in ovarian cancer by promoting a shift in Mcl1-mediated DNA repair pathway from HR to NHEJ.

Article References: Sheng, JJ., He, Y., Liu, PW. et al. GX15-070 enhances niraparib efficacy in ovarian cancer by promoting a shift in Mcl1-mediated DNA repair pathway from HR to NHEJ. J Transl Med 23, 1262 (2025). https://doi.org/10.1186/s12967-025-07284-7

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12967-025-07284-7

Keywords: Ovarian cancer, DNA repair pathways, PARP inhibition, GX15-070, Mcl1, NHEJ, HR.

The innovative therapeutic approach combines alnodesertib, a targeted ATR inhibitor, with a low dose of irinotecan, a chemotherapy agent known to induce DNA damage. By exploiting the vulnerability of cancer cells lacking ATM—an essential protein responsible for detecting and initiating repair of DNA double-strand breaks—the combination therapy effectively disrupts cancer cell survival. While irinotecan damages the cancer cell DNA, alnodesertib blocks the ATR protein’s activity, preventing the cell’s ability to mend the induced damage, ultimately leading to cancer cell death.

Susanna Ulahannan, M.D., an oncologist at the University of Oklahoma and the national principal investigator for the colorectal cancer cohort in the STELLA trial, describes the treatment as a “triple hit.” This characterization reflects the targeted nature of the intervention directed specifically at ATM-deficient tumors, and the synergistic action of two agents: one that induces lethal DNA damage and the other that disables the cellular repair machinery.

The scientific rationale behind this combination lies in the interdependent roles of ATM and ATR proteins within the DNA damage response (DDR) pathway. ATM primarily responds to DNA double-strand breaks by activating repair pathways and cell-cycle checkpoints. Tumors deficient in ATM are inherently compromised in their ability to detect and resolve DNA damage. Consequently, inhibiting ATR in these cells with alnodesertib exacerbates genomic instability, tipping cancer cells toward apoptosis. This approach selectively targets malignant cells while sparing normal cells with intact DNA repair systems, potentially minimizing systemic toxicity.

Clinical outcomes from the trial have been encouraging. A significant portion of patients presenting ATM-deficient tumors exhibited measurable tumor shrinkage following treatment, an achievement noteworthy given the limited options available for metastatic colorectal cancer after multiple lines of prior therapy. These results underscore the potential of precision medicine strategies that tailor treatment based on tumor genetics and biology.

The combination’s Fast Track Designation emphasizes the urgent need for effective therapies in metastatic colorectal cancer, particularly as current options have been limited and disease prognosis remains poor. Colorectal cancer remains a leading cause of cancer-related deaths worldwide, with projections estimating over 154,000 new diagnoses and approximately 52,000 deaths in 2025 alone in the United States. Furthermore, the rising incidence of colorectal cancer in younger populations under 50 years old adds urgency to the development of novel interventions.

Mechanistically, irinotecan exerts antitumor effects by inhibiting topoisomerase I, an enzyme that alleviates DNA supercoiling during replication. Its inhibition leads to DNA breaks that, if unrepaired, cause replication fork collapse and cell death. In tandem, alnodesertib’s inhibition of ATR prevents the activation of cell cycle checkpoints and DDR pathways essential to the survival of cancer cells facing replication stress.

This clinical innovation showcases the growing trend of exploiting synthetic lethality in oncology. By identifying genetic or functional weaknesses in cancer cells—such as ATM deficiency—and targeting compensatory pathways like ATR, researchers can induce selective tumor cell death. Such strategies represent a paradigm shift from traditional cytotoxic therapies toward precision-targeted treatments with potentially improved efficacy and reduced toxicity.

The STELLA trial’s design incorporated patients who had undergone at least two prior colorectal cancer treatments without achieving durable responses. The marked tumor responses observed in this heavily pretreated cohort highlight the combination’s therapeutic promise even in resistant disease settings. Ongoing research will further clarify optimal patient selection, dosing strategies, and long-term outcomes associated with this approach.

In summary, the therapeutic synergy between alnodesertib and irinotecan embodies a novel and rational strategy that targets the DNA repair vulnerabilities of metastatic colorectal cancer. The positive clinical trial data have secured FDA Fast Track Designation, expediting the pathway toward broader clinical application. As research continues, this approach may redefine the standard of care for a patient population with historically limited options, offering renewed hope for improved survival and quality of life.

Subject of Research: People
Article Title: Not provided
News Publication Date: Not provided
Web References: https://www.cancer.org/cancer/types/colon-rectal-cancer/about/key-statistics.html
References: Not provided
Image Credits: University of Oklahoma
Keywords: Colorectal cancer, Chemotherapy, Cancer treatments, Combination therapies, DNA repair genes

The XRCC3 gene is an essential part of the cellular machinery responsible for DNA repair. Variants, or polymorphisms, within this gene can significantly affect how the body responds to DNA damage, a process intrinsically linked with cancer development. Understanding these polymorphisms is critical, as they may serve as biomarkers for identifying individuals at heightened risk of developing thyroid cancer. With thyroid cancer rates climbing globally, the urgency of comprehensively evaluating genetic factors such as XRCC3 cannot be overstated.

In the study by Khosravi-Mashzi and colleagues, over several thousand cases were examined, contributing to a well-rounded view of how XRCC3 variations impact thyroid cancer susceptibility across different populations. The reliability of their findings stems from rigorous methodologies, including meta-analyses that aggregate data from multiple studies. This robust approach lends credibility to their conclusions and provides a solid foundation for possible clinical applications.

The implications of XRCC3 polymorphisms extend beyond mere identification of risk factors; they also pave the way for personalized medicine. By pinpointing which individuals are genetically predisposed to thyroid cancer, healthcare providers can tailor screening processes and preventive strategies accordingly. This could mean enhanced surveillance for specific patient groups or the development of targeted therapies aimed at those most susceptible to the disease.

Interestingly, the study also highlights geographic and ethnic variations in polymorphism prevalence, suggesting that environmental factors might interact with genetic predispositions. These nuances underline the complexities of cancer genetics, revealing that thyroid cancer is not a monolithic disease but rather a tapestry woven from numerous threads of genetic and environmental influences. This realization serves as a call to action for future research, urging scientists to explore these interactions more thoroughly.

As we peer deeper into the connection between XRCC3 polymorphisms and thyroid cancer, the findings raise critical questions about molecular pathways that govern cancer progression. It is hypothesized that certain polymorphisms may lead to impaired DNA damage repair mechanisms, thereby allowing aberrant cellular growth and tumor formation. Investigating the specific mechanisms at play will be paramount in formulating targeted interventions.

Moreover, the study enriches the existing literature by integrating findings from various populations, thereby unveiling the global relevance of XRCC3 polymorphisms in the context of thyroid cancer. Such comprehensive assessments are vital for understanding the broader epidemiological patterns of this malignancy. They also highlight the significance of collaborative research efforts, as pooling data across borders can lead to discoveries that individual studies may miss.

In addition to the genetic focus, the researchers have called for integrative approaches that include lifestyle and environmental assessments. While genetics lays a crucial foundation, it must be complemented by an exploration of extrinsic factors such as diet, exposure to radiation, and hormonal influences that could exacerbate genetic susceptibilities. This holistic view is essential if we hope to tackle thyroid cancer in a manner that is both effective and sustainable.

Interestingly, the research team emphasizes that greater awareness of XRCC3’s role could lead to improved public health messaging. By informing populations about their genetic predispositions, it may be possible to foster proactive health behaviors that can mitigate risk. For instance, individuals identified with certain XRCC3 polymorphisms could be educated about regular thyroid screenings or lifestyle changes that may lower their cancer risk.

The findings also pave the way for novel therapeutic avenues. Understanding which patients carry specific XRCC3 polymorphisms might inform treatment decisions, particularly regarding the efficacy of DNA repair-targeting therapies. These insights could ultimately lead to the development of personalized treatment regimens that are not only more effective but also reduce the risk of adverse effects.

As the research community continues to grapple with the intricacies of cancer genetics, studies like the one by Khosravi-Mashzi et al. provide a crucial framework for future investigations. The integration of genetic insights with clinical practice holds the potential to revolutionize how thyroid cancer is understood and treated, emphasizing the importance of ongoing research in this space.

Ultimately, the exploration of XRCC3 polymorphisms casts a spotlight on a pivotal but often overlooked aspect of cancer biology. As we endeavor to decode the complexities of thyroid cancer, embracing a multifaceted approach that includes genetics, lifestyle, and environmental factors will be essential in our quest to improve outcomes for patients worldwide. The dialogue sparked by this research is more than academic; it offers a glimpse into a future where personalized cancer care may significantly improve survival rates and quality of life for those affected by thyroid malignancies.

As our understanding of XRCC3 polymorphisms deepens, one cannot help but reflect on the interconnectedness of knowledge, research, and patient care. It emphasizes the need for an interdisciplinary approach that unites geneticists, oncologists, epidemiologists, and public health experts. Together, they can forge pathways that not only enhance our understanding of thyroid cancer but also translate that understanding into actionable health strategies and innovations.

In conclusion, Khosravi-Mashzi and colleagues have opened a door to a critical area of thyroid cancer research, equipped with the tools needed to delve deeper into the genetic factors that contribute to this growing public health concern. The journey ahead is fraught with challenges but also brimming with potential for breakthroughs that can change the cancer care landscape. We stand on the precipice of new understanding, eager to embrace the wealth of knowledge that awaits.

Subject of Research: Association between XRCC3 polymorphisms and thyroid cancer susceptibility.

Article Title: A comprehensive compilation of data on the association between XRCC3 polymorphisms and thyroid cancer susceptibility.

Article References:

Khosravi-Mashzi, M., HaghighiKian, S.M., Naseri, A. et al. A comprehensive compilation of data on the association between XRCC3 polymorphisms and thyroid cancer susceptibility.
BMC Endocr Disord 25, 231 (2025). https://doi.org/10.1186/s12902-025-02044-6

Image Credits: AI Generated

DOI: 10.1186/s12902-025-02044-6

Keywords: XRCC3, polymorphisms, thyroid cancer, susceptibility, DNA repair, personalized medicine, genetics, public health.

BRCA2, or Breast Cancer 2 gene, is a pivotal gene that encodes a protein responsible for maintaining genomic stability. Mutations in BRCA2 are well-associated with a significantly heightened risk of developing breast and ovarian cancers. While its role in the repair of DNA double-strand breaks through homologous recombination is established, the nuances of BRCA2’s transcription remain elusive. This study delves into the gene’s transcriptional landscape, paving the way for new insights into cancer predisposition and prevention strategies.

The researchers utilized the Hybrid-seq methodology, which combines the advantages of both long-form and short-form sequencing techniques. This method allows for a comprehensive capture of the entire transcriptome, ensuring that even the most complex variants of BRCA2 transcripts are identified and characterized. By overcoming the limitations of traditional sequencing methods, Hybrid-seq enables the elucidation of previously unrecognized splice variants and regulatory elements within the BRCA2 gene.

Upon examining the transcriptional profiles generated through Hybrid-seq, the research team uncovered an intricate network of alternative splicing events. This discovery emphasizes that BRCA2 is not merely a static gene with a set number of transcripts; instead, it operates within a dynamic framework where various isoforms can potentially influence protein function and gene expression control. This has profound implications for understanding how specific BRCA2 mutations manifest in cancer phenotypes.

Furthermore, the study identified novel regulatory elements that modulate BRCA2 transcription in response to DNA damage signaling. These findings suggest that the expression levels of BRCA2 may vary significantly under different cellular stress conditions, which might contribute to the development of cancer when these regulatory pathways malfunction. The research team speculates that the dysregulation of BRCA2 transcription in the context of mutagenic stress may be a critical factor underlying tumorigenesis in BRCA2 mutation carriers.

The implications of these advances extend beyond theoretical considerations. With greater insight into BRCA2 transcription, we may refine personalized medicine approaches for individuals with BRCA2-related cancers. Understanding specific splice variants or regulatory mechanisms could facilitate more targeted interventions, whether it be through tailored surveillance strategies or novel therapeutic modalities that address the root of genomic instability.

Moreover, the study highlights the potential for leveraging Hybrid-seq technology in other research domains, particularly in exploring gene expression patterns associated with complex diseases. The robustness of Hybrid-seq in unveiling diverse transcriptomic landscapes could greatly enhance our capacity to identify key regulatory networks in various pathological contexts beyond just BRCA2.

Public health discussions around genetic testing often focus on the clear-cut aspects of mutation detection; however, this research underscores the necessity of understanding the full range of gene expression variations. For those at risk of hereditary cancers, the intricate details of how BRCA2 is transcribed can yield critical insights that go beyond binary mutation status.

As genetic counseling continues to evolve, the knowledge gained from this study could lead to improved communication between patients and healthcare providers. It calls for a reassessment of how genetic risk is conveyed, emphasizing the importance of incorporating insights about transcriptional complexity into risk assessment and management discussions.

The research also beckons a futuristic view where transcriptomic profiling may become a standard part of genetic counseling. It raises questions about adopting comprehensive genetic assessments that transcend simple variant identification, looking instead at the broader picture of gene expression regulation.

In conclusion, the work spearheaded by Adamopoulos and his colleagues contributes significantly to our understanding of BRCA2’s transcriptional intricacies. By deploying Hybrid-seq, the study lays a foundation for future research aimed at demystifying the complexities of this influential gene. As we continue to unravel the cryptic layers of genetic regulation, we stand on the brink of a new era in precision oncology, where targeted interventions are guided not just by the presence of mutations but by a nuanced understanding of gene behavior.

In a world where the fight against cancer is paramount, such advances are not only timely but essential. The road ahead holds promise for enhanced cancer prevention strategies, early detection methods, and the development of novel therapeutics that could stem from these newfound understandings of the BRCA2 gene.

As scientific inquiry advances, it becomes increasingly evident that the complexity of gene expression demands our full attention. The findings from this research remind us that the story of each gene is multifaceted and that ongoing exploration is critical to advancing human health.

The implications of this research reach far beyond the laboratory, offering hope to countless individuals grappling with the specter of hereditary cancer. As we decode the complexities of the BRCA2 gene, we inch closer to a future where cancer outcomes can be significantly improved through precise and informed medical strategies.

Subject of Research: The transcriptional complexity of the BRCA2 gene and its implications in cancer genomics.

Article Title: Decoding the Transcriptional Complexity of the Human BRCA2 DNA Repair Gene Using Hybrid-seq.

Article References: Adamopoulos, P.G., Boti, M.A., Athanasopoulou, K. et al. Decoding the Transcriptional Complexity of the Human BRCA2 DNA Repair Gene Using Hybrid-seq. Biochem Genet (2025). https://doi.org/10.1007/s10528-025-11180-6

Image Credits: AI Generated

DOI: Not provided.

Keywords: BRCA2, gene transcription, cancer genetics, Hybrid-seq, DNA repair, genomic stability, alternative splicing, cancer prevention strategies.

Connexin 43, traditionally known as a gap junction protein facilitating intercellular communication, has recently come under the scientific spotlight for its multifunctional role in cancer biology. The current research identifies Cx43 as a crucial enhancer of cancer cell sensitivity to inhibitors targeting the BRAF/MEK signaling axis. These inhibitors have transformed the treatment landscape for patients with BRAF-mutant tumors; however, resistance invariably emerges. The novel insight that Cx43 reduces DNA repair capacity invites the intriguing hypothesis that modulating Cx43 levels or function might overcome or delay resistance development.

Mechanistically, this study shows that Cx43 expression correlates with impaired homologous recombination (HR) repair pathways, the very systems cancer cells rely on to mend double-strand breaks induced by genotoxic stress or therapeutic agents. By reducing the efficiency of HR, Cx43 effectively sabotages DNA repair machinery, rendering cancer cells more susceptible to DNA damage accumulation when exposed to BRAF and MEK inhibitors. This sensitization translates to increased apoptosis and tumor cell death, elevating the clinical utility of existing kinase inhibitors.

The investigators employed a comprehensive array of molecular and cellular techniques, including gene editing to manipulate Cx43 expression, high-resolution microscopy to observe gap junction dynamics, and sophisticated assays to quantify DNA repair proficiency. Their data revealed that Cx43 knockdown restored HR capacity and diminished drug sensitivity, whereas overexpression had the opposite effect. Such findings underscore the causative role of Cx43 levels in modulating DNA repair pathways and therapeutic outcomes.

This research also delves into the signaling cascades downstream of Cx43, implicating the disruption of key DNA repair proteins such as RAD51 and BRCA1. The reduction in protein levels and foci formation critical for homologous recombination suggests that Cx43 interferes at multiple points within the repair pathway. Notably, this interference does not arise from transcriptional changes but rather post-translational modulation, highlighting a complex regulatory mechanism that warrants further exploration.

From a clinical perspective, these insights raise the prospect of using Cx43 as a biomarker to predict patient responsiveness to BRAF/MEK inhibitors. High Cx43 expression in tumor biopsies could identify individuals likely to benefit from kinase inhibitor monotherapy or combination regimens that capitalize on impaired DNA repair. Conversely, tumors lacking adequate Cx43 might require additional therapeutic modalities to overcome intrinsic drug resistance.

Additionally, combining BRAF/MEK inhibitors with agents targeting DNA repair pathways, such as PARP inhibitors, might yield synergistic effects in Cx43-expressing tumors. This combinatorial approach could exploit synthetic lethality, where simultaneous compromise of DNA repair and oncogenic signaling overwhelms the tumor’s survival mechanisms, maximizing therapeutic efficacy while potentially reducing drug doses and side effects.

The study’s broader implications extend to understanding tumor heterogeneity and microenvironmental influences on drug response. Since Cx43 is central to cell-cell communication, its role in shaping the tumor niche and facilitating intercellular transfer of survival signals or DNA repair factors could influence how tumors adapt to targeted therapies. Dissecting these interactions might reveal novel vulnerabilities exploitable for intervention.

Moreover, the findings challenge the conventional perception of connexins solely as structural proteins by positioning Cx43 as a dynamic regulator of intracellular signaling networks linked to DNA damage response. This conceptual shift could inspire future research into other connexin family members and their potential roles in cancer progression and therapy resistance.

Importantly, the research team highlights the temporal aspect of Cx43’s effect, noting that Cx43-mediated DNA repair disruption appears most critical during early drug exposure phases. This timing could inform treatment scheduling and the design of sequential or adaptive therapeutic regimens aimed at sustaining maximal tumor cell kill while minimizing resistance.

The neurobiological functions of Cx43 and its implication in various cancers necessitate a careful assessment of potential off-target effects or toxicity associated with manipulating this protein therapeutically. The study suggests that targeted delivery systems or context-specific modulation might mitigate such concerns, enabling the safe translation of these findings into clinical applications.

These results also raise intriguing questions regarding the evolutionary significance of Cx43’s dual roles in maintaining tissue homeostasis and modulating DNA repair in pathological conditions. Understanding how cancer cells exploit such native cellular mechanisms could unlock new avenues for intervention beyond genetic mutations to encompass broader systems biology strategies.

The meticulous experimental design and robust validation performed by Varela-Vázquez et al. provide a compelling rationale for initiating clinical trials that integrate Cx43 status into patient stratification. Such trials could evaluate whether Cx43-centric approaches enhance long-term survival and delay resistance onset in patients receiving BRAF or MEK inhibitor therapy.

In conclusion, this landmark study uncovers a previously unappreciated function of connexin 43 in sensitizing BRAF-mutant tumors to kinase inhibitors through the attenuation of DNA repair pathways. By bridging molecular biology, oncology, and therapeutic innovation, these findings could revolutionize personalized cancer treatment paradigms and open fresh horizons for combating drug-resistant malignancies.

Subject of Research: The role of connexin 43 (Cx43) in modulating DNA repair capacity and enhancing the efficacy of BRAF/MEK inhibitors in cancer therapy.

Article Title: Cx43 enhances response to BRAF/MEK inhibitors by reducing DNA repair capacity.

Article References:
Varela-Vázquez, A., Guitián-Caamaño, A., Carpintero-Fernández, P. et al. Cx43 enhances response to BRAF/MEK inhibitors by reducing DNA repair capacity. Nat Commun 16, 6168 (2025). https://doi.org/10.1038/s41467-025-60971-3

Image Credits: AI Generated